It is quite interesting. I was much more animated about the...

It is quite interesting. I was much more animated about the contract a while back but I have read a number of articles, even as recently as this week, where I read 2 articles about pharmaceutical companies being in arrangements where they receive a longer term royalty after selling the rights to a drug. One of them was a post on HC about a drug that Pfizer still took a cut of after selling/licensing it.

It seems like its not an uncommon practice and did not stop future acquisition or significantly impact its prospects.

I think some certainty in any arrangements with Acadia would be beneficial - in terms of a possible cut they may receive for future conditions that are on their radar etc.